Background
==========

Breast cancer is a leading gynecologic cancer. Currently, neoadjuvant chemotherapy (NCT) is widely used for the treatment of early breast cancer \[[@b1-medscimonit-23-4321]\]. However, response to chemotherapy varies among patients, even when they have identical histological and molecular subtypes \[[@b2-medscimonit-23-4321],[@b3-medscimonit-23-4321]\]. Pathological complete response (pCR) has been implicated as a surrogate indicator of long-term clinical benefit, such as disease-free survival and overall survival (OS), by many studies \[[@b4-medscimonit-23-4321],[@b5-medscimonit-23-4321]\]. To date, only negative estrogen receptor (ER) status \[[@b6-medscimonit-23-4321]\] and loss of bcl-2 \[[@b7-medscimonit-23-4321]\] have been suggested as predictors of pCR in patients receiving neoadjuvant chemotherapy for operable and locally advanced breast cancer.

However, the mechanisms underlying pCR are largely unknown. Here, we attempted to use RNA sequencing (RNA-seq) technique to seek key genes and transcription factors that may contribute to pCR by comparing the transcriptome data between breast cancer patients with pCR to chemotherapy and those with non-pCR.

Material and Methods
====================

Patient enrollment and sampling
-------------------------------

Patients diagnosed with invasive breast cancer were included in this study. The inclusion criteria were: (1) patients with stage II or IIIA, operable breast cancer; (2) without distant metastasis; (3) without other serious disease, who can complete the chemotherapy as planned; (4) at least 10 ug total RNA can be extracted from the frozen biopsy tissue.

Finally, 6 patients, including 3 showing pCR (MXL-3-2, MXL-5-1 and MXL-P2) and 3 showing non-pCR (MXL-N1, MXL-N2 and MXL-1-3), were included. Written informed consent was provided by each patient and volunteer before sampling.

Total RNA extraction, library construction, and sequencing
----------------------------------------------------------

A total of 10 g RNA was extracted from the frozen biopsy tissue of each patient, then poly(A)^+^ mRNA was isolated using Sera-mag Magnetic Oligo(dT) Beads (Thermo, part \# 1004815). Afterwards, the purified RNA was broken into short segments in Fragment buffer. Next, reverse transcription was performed to construct a cDNA library. RNA concentration was measured with a Qubit^®^ 2.0 Fluorometer and RNA integrity number (RIN) was measured by use of a Bioanalyzer 2100 (Agilent, CA, USA). Sequencing was performed on the HiSeq2000 platform (Illumina Inc., San Diego, CA) and single-end reads (50 bp in length) were generated.

Sequence quality control and alignment
--------------------------------------

First, reads were filtered by removing reads containing more than 40% bases with quality value \<Q20 and reads containing more than 4% N bases. Sequence quality control was done with the fastx_toolkit. Next, clean reads were mapped to the human reference genome hg19 using TopHat 2.1.1 software (download site: *<http://ccb.jhu.edu/software/tophat/index.shtml>*).

Identification of differentially expressed genes correlated with mild and severe pneumonia
------------------------------------------------------------------------------------------

Reads count data were first preprocessed using the edgeR package of R (version 3.1.0) \[[@b8-medscimonit-23-4321]\], which were then processed into log~2~-counts per million (logCPM) matrix by voom method using the R/limma package. Then, differential expression analysis between the pCR and NpCR groups was performed using the R/limma package, and \| log~2~FC \| \>1 and p\<0.05 were used as cutoffs for a differentially expressed gene (DEG). A heat map was also used to display the gene expression profile of differentially expressed genes, based on the hierarchical clustering results using R package gplots \[[@b9-medscimonit-23-4321]\].

Construction of a protein-protein interaction network
-----------------------------------------------------

DEGs were submitted to the online tool STRING \[[@b10-medscimonit-23-4321]\] (version: 10.0; *<http://string-db.org/>*) to identify protein-protein interaction (PPI) pairs. Only pairs with PPI score of 0.7 or higher were retained to construct a PPI network using Cytoscape \[[@b11-medscimonit-23-4321]\].

Key proteins in the PPI network were identified by comparing the following parameters: degree of centrality \[[@b12-medscimonit-23-4321]\], betweenness centrality \[[@b13-medscimonit-23-4321]\], subgraph centrality \[[@b14-medscimonit-23-4321]\], and closeness Centrality) \[[@b15-medscimonit-23-4321]\]. The parameters were calculated using a cytoscape plug-in CytoNCA \[[@b16-medscimonit-23-4321]\].

Next, module analysis was performed to indent the subnetwork from the PPI network using ClusterONE \[[@b17-medscimonit-23-4321]\]. Pathway enrichment analysis of the genes in the module was also performed using DAVID; p\<0.05 was used as a cutoff.

Prediction of transcription factors and construction of a transcription factor-gene network
-------------------------------------------------------------------------------------------

Transcriptional regulators are responsible for the transcriptional regulation of gene expression \[[@b18-medscimonit-23-4321]\]. Transcriptional factors that may regulate the DEGs in a module were searched by use of the anplug-in iRegulon \[[@b19-medscimonit-23-4321]\] of Cytoscape, which integrates transcription factor information from the databases Transfac, Jaspar, Encode, Swissregulon, and Homer. The parameters were set as follows: Minimum identity between orthologous genes: 0.05, and Maximum false discovery rate on motif similarity: 0.001. A gene-transcription factor pair with normalized enrichment score (NES) \>3 was retained.

Result
======

Quality control of reads and statistics
---------------------------------------

Quality statistics of reads are shown in [Table 1](#t1-medscimonit-23-4321){ref-type="table"}.

Identification of DEGs
----------------------

A total of 673 DEGs were identified in patients with pCR to chemotherapy, including 419 upregulated ones and 254 downregulated ones. Overall, the identified DEGs can distinguish the pneumonia samples from the control sample ([Figure 1](#f1-medscimonit-23-4321){ref-type="fig"}).

The upregulated DEGs were significantly enriched in 12 KEGG pathways, and the downregulated ones were significantly enriched in 2 pathways.

PPI network construction and module analysis
--------------------------------------------

The constructed PPI network consisted of 276 proteins forming 471 PPI pairs ([Figure 2](#f2-medscimonit-23-4321){ref-type="fig"}). The top 10 proteins for each centrality parameter are listed in [Table 2](#t2-medscimonit-23-4321){ref-type="table"}.

One subnetwork was obtained, which included 18 protein nodes forming 79 protein-protein interaction pairs ([Figure 3](#f3-medscimonit-23-4321){ref-type="fig"}). More importantly, the heatmap revealed that these 18 genes can accurately distinguish the pCR samples and NpCR samples ([Figure 4](#f4-medscimonit-23-4321){ref-type="fig"}). Pathway enrichment analysis revealed that *PLCB4* and *ADCY6* were enriched in the renin secretion pathway, gastric acid secretion pathway, gap junction pathway, inflammatory mediator regulation of TRP channels pathway, retrograde endocannabinoid signaling pathway, melanogenesis pathway, cGMP-PKG signaling pathway, calcium signaling pathway, chemokine signaling pathway, cAMP signaling pathway, and rap1 signaling pathway. CNR1 was enriched in the neuroactive ligand-receptor interaction pathway, the retrograde endocannabinoid signaling pathway, and the rap1 signaling pathway ([Table 3](#t3-medscimonit-23-4321){ref-type="table"}).

Construction of transcription factor-gene network
-------------------------------------------------

The transcription factor-gene network consisted of 15 transcription factors and 16 targeted genes ([Figure 5](#f5-medscimonit-23-4321){ref-type="fig"}). These transcription factors were also differentially expressed: 5 downregulated and 10 upregulated.

Discussions
===========

Because pCR to chemotherapy is recognized as an independent prognostic and predictive factor for survival of BC patients, we attempted to learn more about what contributes to the difference between patients with pCR and those with NpCR. Based on the transcriptome data from RNA-seq, we first identified DEGs that were associated pCR, and then tried to find key proteins (such as PLCB4, ADCY6, CNR1, and MAPK14) to from a protein-protein interaction perspective.

Among the upregulated genes, *PLCB4* and *ADCY6* were speculated to contribute to pCR to chemotherapy via multiple pathways, such as via renin secretion, gastric acid secretion, gap junction, inflammatory mediator regulation of TRP channels, retrograde endocannabinoid signaling, melanogenesis, cGMP-PKG signaling pathway, calcium signaling pathway, chemokine signaling pathway, cAMP signaling pathway, and rap1 signaling pathway. CNR1 was a downregulated gene, which was enriched in pathways of neuroactive ligand-receptor interaction, retrograde endocannabinoid signaling, and rap1 signaling pathway.

*ADCY6* encodes adenylyl cyclase 6, which is a membrane-associated enzyme catalyzing the formation of the secondary messenger cyclic adenosine monophosphate (cAMP). The differential expression of this gene has also been reported in breast cancer \[[@b20-medscimonit-23-4321]\] and ovarian carcinoma by microarray analysis \[[@b21-medscimonit-23-4321]\]. By microarray analysis, ADCY6 expression was found to be decreased by 2-fold more in the 81-fold gemcitabine-resistant variant MiaPaCa2-RG than in the gemcitabine-sensitive cell line MiaPaCa2 \[[@b22-medscimonit-23-4321]\], suggesting that high ADCY6 expression is associated with gemcitabine sensitivity. This seems to agree with its upregulation in patients with pCR to chemotherapy.

*PLCB4* encodes an enzyme 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta-4, which catalyzes the formation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol from phosphatidylinositol 4,5-bisphosphate (PIP2). Woodfield et al. identified the primary gene targets of TFAP2C in hormone responsive breast carcinoma cells and found that PLCB4 was induced by TFAP2C \[[@b23-medscimonit-23-4321]\]. TFAP2C is a member of the retinoic acid-inducible developmentally regulated family of AP-2 factors, which regulates its target genes via a helix-loop-helix motif \[[@b24-medscimonit-23-4321]\] and has been suggested to have a critical role in breast cancer \[[@b25-medscimonit-23-4321]--[@b27-medscimonit-23-4321]\]. Thus, we supposed that PLCB4 may also have a role in the pathogenesis of breast cancer. Zheng et al. reported that *PLCB4* was among the 12 genes showing significant upregulated expression (ratio \>5) in acute myeloid leukemia cells (HL-60/MDR) with resistance to 6 ordinary antitumor drugs (Vincristine, Adriamycin, Etoposide, Daunorubicin, Mitomycin C, and Cyclophosphamide) \[[@b28-medscimonit-23-4321]\], suggesting that PLCB4 contributes to resistance to antitumor drugs. However, this seems contradictory to our finding here that PLCB4 was upregulated in patients with complete response to chemotherapy. Thus, whether this helps to induce pCR to chemotherapy needs to be further studied. Further pathway enrichment analysis suggests that this gene may contribute to pCR to chemotherapy.

*CNR1* was downregulated and encodes a G protein-coupled cannabinoid receptor (also known as cannabinoid CB1), located primarily in the central nervous system, and its activation is necessary for the antiemetic action of cannabinoids used for preventing emesis in cancer patients receiving chemotherapy \[[@b29-medscimonit-23-4321]\]. Remarkably, decrease in its expression has also been reported in chemosensitive serous epithelial ovarian cancer tumors \[[@b30-medscimonit-23-4321]\], suggesting that this gene may also have a role in breast cancer.

Interestingly, these 3 genes were predicted to be regulated by transcription factors such as BARX2, CRX, TOX, POU2F1, VAX2, HOXA6, HOXB7, MYBL1, and NFATC2. Some of these transcription factors were upregulated and some were downregulated, indicating that their regulation upon the expression of a gene is complicated. Among them, *BARX2* was found to be downregulated in patients showing pCR to chemotherapy. *BARX2* is located within a minimal region at 11q25, which has been reported to promote breast cancer progression \[[@b31-medscimonit-23-4321]\]. Sellar et al. reported that this gene can modulate cisplatin sensitivity in human epithelial ovarian cancer \[[@b32-medscimonit-23-4321]\]. In contrast, HOXA6 and HOXB7 were upregulated in patients showing pCR to chemotherapy. These 2 transcription factors are encoded by the homeobox (HOX) gene family, and were found to have an important role in embryogenesis and differentiation of adult cells \[[@b33-medscimonit-23-4321]\]. Some of the HOX members (Hoxa9, Hoxa10, and Hoxa11) have been suggested to contribute to epithelial ovarian cancer \[[@b34-medscimonit-23-4321]\].

Conclusions
===========

By RNA-seq, we found some key genes that may contribute to pCR to chemotherapy, such as *PLCB4, ADCY6, CNR1*, as well as some transcription factors. Their roles need to be further validated by experimental evidence.
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###### 

Quality statistics of reads.

                 MXL-1-3    MXL-N1    MXL-N2    MXL-3-2    MXL-5-1    MXL-P2
  -------------- ---------- --------- --------- ---------- ---------- ---------
  Total reads    13118494   9277266   8370271   10284940   10998042   9655503
  Length reads   50         51        51        50         50         51
  Q20            13099904   9230891   8334022   10269116   10982423   9607845
  Q20%           99.86%     99.50%    99.57%    99.85%     99.86%     99.51%
  Q10            13118494   9276514   8369620   10284940   10998042   9654775
  Q10%           100.00%    99.99%    99.99%    100.00%    100.00%    99.99%
  Clean reads    10690546   6365594   5792665   8402125    8830451    6619228
  Valid ratio    81.49%     68.61%    69.21%    81.69%     80.29%     68.55%

###### 

The top 10 proteins for each centrality parameter in the protein-protein interaction network.

  Subgragh   Degree      Betweenness   Closeness                                  
  ---------- ----------- ------------- ----------- --------- ----------- -------- ----------
  FPR2       3416.2122   MCHR1         16          PLCG1     6810.7944   EDN1     0.012742
  EDN1       3354.0837   ADCY6         15          PPP2R1A   5778.3564   PLCG1    0.012732
  AVP        2874.9324   PLCG1         15          MTOR      5671.6304   PIK3CD   0.01272
  GCGR       2680.8079   PIK3CD        15          MAP2K2    5196.929    BDNF     0.012717
  GNA14      2441.132    FPR2          14          EDN1      5053.5815   MAP2K2   0.012717
  CCK        2312.8115   TRIO          14          BDNF      4729.795    GNA14    0.012713
  PLCB4      2118.2554   AVP           13          POLR2H    4465.244    MTOR     0.012711
  TRIO       2074.557    PLCB4         13          ADCY6     4349.1655   PXN      0.012711
  EDN3       2024.1368   MAPK14        13          CTNNA1    3852.7537   AVP      0.012703

###### 

KEGG pathway enrichemnt of genes in the protein-protein interaction subnetwork.

  Term                                                         P value    Genes
  ------------------------------------------------------------ ---------- ------------------------------------------------------
  hsa04080: Neuroactive ligand-receptor interaction            1.05E-07   MCHR1, SSTR2, CNR1, FPR2, VIPR1, ADORA1, HTR2C, GCGR
  hsa04924: Renin secretion                                    5.28E-03   PLCB4, ADCY6, ADORA1
  hsa04971: Gastric acid secretion                             6.82E-03   SSTR2, PLCB4, ADCY6
  hsa04540: Gap junction                                       9.79E-03   PLCB4, ADCY6, HTR2C
  hsa04750: Inflammatory mediator regulation of TRP channels   1.18E-02   PLCB4, ADCY6, HTR2C
  hsa04723: Retrograde endocannabinoid signaling               1.18E-02   PLCB4, CNR1, ADCY6
  hsa04916: Melanogenesis                                      1.25E-02   PLCB4, EDN1, ADCY6
  hsa04022: cGMP-PKG signaling pathway                         3.11E-02   PLCB4, ADCY6, ADORA1
  hsa04020: Calcium signaling pathway                          3.58E-02   GNA14, PLCB4, HTR2C
  hsa04062: Chemokine signaling pathway                        3.96E-02   PLCB4, CCR5, ADCY6
  hsa04024: cAMP signaling pathway                             4.44E-02   SSTR2, ADCY6, ADORA1
  hsa04015: Rap1 signaling pathway                             4.99E-02   PLCB4, CNR1, ADCY6
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